Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Collage with halftone hand, light bulb and head. Creative idea generation or brainstorm concept vector pop art retro style illustration. Design element for infographic, poster, website

Parkinson’s disease

A Month After Stunning Schizophrenia Fail, AbbVie’s Other Cerevel Asset Shines Again

Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie announced the Phase II failure of another key Cerevel asset, emraclidine.

December 9, 2024

1 min read

Annalee Armstrong

Merck Research Laboratories in South San Francisco, California

Lymphoma

Merck Touts 100% Complete Response Rate for Anti-ROR1 ADC as First-Line Lymphoma Treatment

Analysts called the data “very competitive” but raised questions about safety. Merck gained ownership of the ADC when it acquired VelosBio in November 2020 for $2.75 billion.

December 9, 2024

2 min read

Tristan Manalac

Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.

Obesity

BioAge Crashes After Axing Phase II Obesity Study

The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen announced underwhelming mid-stage data for MariTide.

December 9, 2024

2 min read

Tristan Manalac

A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.

Mergers & acquisitions

Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and Lilly, a broad coalition of unions and consumer groups and at least one senator.

December 9, 2024

2 min read

Tristan Manalac

Note paper with blood donation concept on red background

Sickle cell disease

Vertex, Beam Report SCD Cell and Gene Therapies Advances at ASH 2024

Vertex unveiled long-term durability data for Casgevy, while Beam presented Phase I/II findings for its investigational base editor BEAM-101, building up to a BLA by late 2026.

December 9, 2024

2 min read

Tristan Manalac

Human or animal cells on blue background. Concept Early stage embryo Medicine scientific concept, Stem cell research and treatment, 3D illustration

Partnered

The Strategic Imperative: Why Early Potency Assay Development Makes or Breaks ATMP Success

Not developing potency assays and gaining knowledge about MOAs early in the drug development process not only can break ATMP success but can cause costs and delays that lead to company closures.

December 9, 2024

7 min read

BioSpace Insights

GLP-1

Evidence Mounts for Potential of GLP-1s in Alzheimer’s Disease

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.

December 9, 2024

6 min read

Heather McKenzie